Market Place
Sourcing Support
Xencor Reports Q3 2024 Financial Results
06 Nov 2024 //
BUSINESSWIRE
Xencor Presents Data On XmAb942 For Inflammatory Bowel Diseases
10 Oct 2024 //
BUSINESSWIRE
Xencor Announces Upcoming Change to Board of Directors
04 Oct 2024 //
BUSINESSWIRE
Xencor Closes Public Offering With Full Exercise Of Underwriters` Option
12 Sep 2024 //
BUSINESSWIRE
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
11 Sep 2024 //
BUSINESSWIRE
Xencor Announces Proposed Public Offering of Common Stock
10 Sep 2024 //
BUSINESSWIRE
PESG Report On Silexion`s RNAi Tech For KRAS-Driven Cancers
09 Sep 2024 //
BUSINESSWIRE
Huonslab Reports Positive PK Study For Trastuzumab/HyDIFFUZE
06 Sep 2024 //
BUSINESSWIRE
Xencor Reports Second Quarter 2024 Financial Results
05 Aug 2024 //
BUSINESSWIRE
Xencor Regains CD20 x CD3 Bispecific T-Cell Engager
13 Jun 2024 //
BUSINESSWIRE
Xencor To Regain Global Rights To Bispecific T-Cell Engager Plamotamab
13 Jun 2024 //
NASDAQ
Xencor Reports First Quarter 2024 Financial Results
09 May 2024 //
BUSINESSWIRE
Xencor Appoints Bart Cornelissen as Chief Financial Officer
09 Apr 2024 //
PRESS RELAESE
Xencor Names Bart Cornelissen as SVP and Chief Financial Officer
09 Apr 2024 //
CONTRACTPHARMA
Insider Sell: President & CEO Bassil Dahiyat Sells 12,528 Shares of Xencor
08 Mar 2024 //
YAHOO FINANCE
Xencor to Present at Upcoming Investor Conferences
28 Feb 2024 //
BUSINESSWIRE
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
BUSINESSWIRE
Xencor to Host Webcast to Review Q4 and Full Year 2023 Financial Results
20 Feb 2024 //
BUSINESSWIRE
Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
BUSINESSWIRE
Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy
02 Jan 2024 //
BUSINESSWIRE
Xencor to Present at the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
BUSINESSWIRE
Xencor pulls back from Genentech cancer pact to cut costs
08 Nov 2023 //
FIERCE BIOTECH
Xencor Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
Xencor Sells Portion of Royalties and Milestones from Ultomiris
07 Nov 2023 //
BUSINESSWIRE
Xencor Presents Data from Multiple XmAb® Programs at the SITC Annual Meeting
03 Nov 2023 //
BUSINESSWIRE
Xencor to Host Third Quarter 2023 Financial Results Webcast
31 Oct 2023 //
BUSINESSWIRE
Montai Health hires first CMO; Finance leader to retire at J&J partner Xencor
27 Oct 2023 //
ENDPTS
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
26 Oct 2023 //
BUSINESSWIRE
Xencor to Present Multiple Posters at the SITC Annual Meeting
27 Sep 2023 //
BUSINESSWIRE
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
19 Sep 2023 //
BUSINESSWIRE
Xencor Reports Second Quarter 2023 Financial Results
03 Aug 2023 //
BUSINESSWIRE
Xencor to Host Second Quarter 2023 Financial Results Webcast
27 Jul 2023 //
BUSINESSWIRE
Xencor reports data from Phase Ia study of XmAb564 in healthy volunteers
31 May 2023 //
CLINICAL TRIALS ARENA
Xencor Presents Clinical Results from Phase 1a Study of XmAb®564
30 May 2023 //
BUSINESSWIRE
Xencor Reports First Quarter 2023 Financial Results
08 May 2023 //
BUSINESSWIRE
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
26 Apr 2023 //
BUSINESSWIRE
Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023
17 Apr 2023 //
BUSINESSWIRE
Xencor to Present Data from Novel XmAb CD28 Bispecific Antibody Programs
14 Mar 2023 //
BUSINESSWIRE
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
BUSINESSWIRE
Xencor to Report Fourth Quarter and Full Year 2022 Financial Results
16 Feb 2023 //
BUSINESSWIRE
Xencor to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
BUSINESSWIRE
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody
06 Feb 2023 //
GLOBENEWSWIRE
Xencor Highlights 2023 Corporate Priorities and Provides Portfolio Updates
09 Jan 2023 //
BUSINESSWIRE
Caris and Xencor Expand Target Discovery Collaboration for Novel XmAb Antibody
05 Jan 2023 //
PR NEWSWIRE
Xencor to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
BUSINESSWIRE
Xencor Presents Data from Phase 1 Study of Plamotamab in Non-Hodgkin Lymphoma
12 Dec 2022 //
BUSINESSWIRE
Xencor Presents Early Clinical Data from Combination Study of Vudalimab
10 Nov 2022 //
PRESS RELEASE
Xencor to Present at Upcoming Investor Conferences
10 Nov 2022 //
PRESS RELEASE
Xencor’s IL2-Fc Cytokine, XmAb564, Expands Regulatory T Cells in Phase 1a
07 Nov 2022 //
PRESS RELEASE
Xencor Reports Third Quarter 2022 Financial Results
07 Nov 2022 //
BUSINESSWIRE
Xencor to Present Data from the Phase 1 Study of Plamotamab in Relapsed
03 Nov 2022 //
BUSINESSWIRE
Xencor to Host Third Quarter 2022 Financial Results Webcast
31 Oct 2022 //
BUSINESSWIRE
Xencor to Present Seven Posters on Multiple Clinical Trials at the SITC
05 Oct 2022 //
BUSINESSWIRE
Xencor Appoints Nancy Valente, M.D., to Board of Directors
09 Sep 2022 //
BUSINESSWIRE
Xencor Reports Second Quarter 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
MorphoSys AG Reports Second Quarter and First Half 2022 Financial Results
03 Aug 2022 //
BUSINESSWIRE
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call
27 Jul 2022 //
BUSINESSWIRE
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb104
26 May 2022 //
BUSINESSWIRE
Xencor culls 2 bispecifics after early-phase data underwhelm
07 May 2022 //
FIERCEBIOTECH
Xencor Reports First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
